Amgen, Transkaryotic, sanofi-aventis renal, gene/cell therapy news

The U.K.'s House of Lords upheld a 2002 decision from the Court of Appeal that Dynepo epoetin delta from TKTX and Aventis, now SAN, did not infringe

Read the full 277 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE